| Ytd | -90.67% | |
| 1y | -96.53% |
| Open | 2.91 | Prev Close | 3.00 | Low | 2.86 | High | 3.07 | Mkt Cap | 14.65M |
| Vol | 47.77K | Avg Vol | 89.87K | EPS | -695.50 | P/E | N/A | Forward P/E | -0.37 |
| Beta | 0.88 | Short Ratio | 1.12 | Inst. Own | 1.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 4.40 | 200-d Avg | 31.57 | 1yr Est | 6.00 |
JAGX News
Company remains sharply focused on its ongoing global development program for crofelemer for rare IF
Major M&A deals this week include: Adobe buys Topaz Labs, Rise Baking Company purchases Jimmy
Company remains sharply focused on its ongoing global development program for crofelemer for rare in
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the company has completed
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that i
Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Scienc
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the results of a preclinic
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, presid
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(13.60) per share which missed the analyst
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) announced tha
Jaguar Health Inc. shares are climbing Wednesday after preliminary FDA talks on Breakthrough Therapy
Preliminary discussion with the Division of Gastroenterology at U.S. Food and Drug Administration (F
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced topline results from the completion of it
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that o
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announce
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it plans to use AI platforms to enhance its d
Crofelemer, under the name Canalevia-CA1, is currently conditionally approved for the sole indicatio
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that t
As announced, Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 up
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that i
Jaguar has received the initial $16M payment related to the company's recently executed US out-l
Jaguar Health Inc (NASDAQ:JAGX) subsidiary, Napo Pharmaceuticals, has struck a new licensing deal wi
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that its wholly-owned subsidiary Napo Pharmaceutic
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that an article published December 29, 20
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it received notice from th
SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, w
Conditional approval extended through December 2026 for the treatment of CID in dogs CID confirmato
Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA condition
This new IP supports crofelemer's global exclusivity in rare pediatric intestinal failure coinci